<DOC>
<DOCNO>EP-0648778</DOCNO> 
<TEXT>
<INVENTION-TITLE>
11-Benzaldoximeestradiene-derivates, a process for their preparation and pharmaceutical compositions containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P3500	A61P3500	A61K3156	C07J4100	A61P1302	A61P1300	A61P1500	A61P1500	C07J7500	A61K31565	C07J4100	A61K31565	A61K3156	C07J7500	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61P	A61K	C07J	A61P	A61P	A61P	A61P	C07J	A61K	C07J	A61K	A61K	C07J	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P35	A61P35	A61K31	C07J41	A61P13	A61P13	A61P15	A61P15	C07J75	A61K31	C07J41	A61K31	A61K31	C07J75	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
11-Benzaldoxime-oestradiene derivatives of the general formula I 
<
IMAGE
>
 and their pharmaceutically acceptable salts, a process for their preparation and pharmaceutical compositions containing them are described. The described compounds display potent antigestagenic effects with lower glucocorticoid activity.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
JENAPHARM GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
JENAPHARM GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
ELGER WALTER DR
</INVENTOR-NAME>
<INVENTOR-NAME>
KAUFMANN GUENTHER DR
</INVENTOR-NAME>
<INVENTOR-NAME>
KURISCHKO ANATOLI DR
</INVENTOR-NAME>
<INVENTOR-NAME>
OETTEL MICHAEL PROF DR
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHUBERT GERD DR
</INVENTOR-NAME>
<INVENTOR-NAME>
SOBECK LOTHAR DR
</INVENTOR-NAME>
<INVENTOR-NAME>
ELGER, WALTER, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
KAUFMANN, GUENTHER, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
KURISCHKO, ANATOLI, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
OETTEL, MICHAEL, PROF. DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHUBERT, GERD, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
SOBECK, LOTHAR, DR.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
11β-benzaldoxime-estra-4,9-derivatives of the general 
formula I 


 
where
 
R
1
 is a hydrogen atom or alkyl residue containing 1-6 
carbon atoms,
 
R
2
 is a hydrogen atom, an alkyl, aryl, aralkyl, or 
alkylaryl group containing 1-10 carbon atoms, an acyl 

residue containing 1-10 carbon atoms, or a residue 
-CONHR
4
 or -COOR
4
,
 
   where R
4
 is a hydrogen atom, an alkyl, aryl, 
aralkyl, or alkylaryl residue containing 1-10 

carbon atoms,
 
R
3
 is a hydrogen atom, an alkyl, aryl, aralkyl, or 
alkylaryl group containing 1-10 carbon atoms,
 
a residue -(CH
2
)
n
-CH
2
X,
 
   where n = 0, 1, or 2, X represents a fluorine, 

chlorine, bromine, or iodine atom, a cyano, 
acido, or rhodano group, a residue OR
5
 or SR
5
,
 
     R
5
 being a hydrogen atom, an alkyl, aryl, 
aralkyl, or alkylaryl residue containing 1-10  

 
carbon atoms, or an acyl residue containing 

1-10 carbon atoms,
 
a residue OR
5
,
 
   in which R5 has the meaning specified above,
 
a residue -(CH
2
)
o
-CH=CH(CH
2
)
p
-R
6
,
 
   where o = 0, 1, 2, or 3 and p = 0, 1, or 2, and 

R
6
 represents a hydrogen atom, an alkyl, aryl, 
aralkyl, or alkylaryl group containing 1-10 

carbon atoms, a hydroxyl group, an alkoxy or 
acyloxy group containing 1-10 carbon atoms,
 
a residue -(CH
2
)
q
C≡CR
7
,
 
   where q = 0, 1, or 2, and R
7
 represents a 
hydrogen atom, a fluorine, chlorine, bromine, or 

iodine atom, an alkyl, aryl, aralkyl, or 
alkylaryl residue containing 1-10 carbon atoms, 

or an acyl residue containing 1-10 carbon atoms,
 
or, in case that Z is -H, R
1
 is -CH
3
 and R
2
 is -H or 
-CH
3
, represents a residue -C≡C-CH
2
OH,
 
Z represents a hydrogen atom, an alkyl, aryl, 

aralkyl, or alkylaryl residue containing 1-10 carbon 
atoms, or an acyl residue containing 1-10 carbon 

atoms, a residue
 
-CONHR
4
 or -COOR
4
,
 
   where R
4
 has the meaning specified above, 
or an alkaline or alkaline-earth metal atom,
 
and their pharmaceutically acceptable salts,
 
with the exception of compounds in which R
1
 is -CH
3
, 
R
2
 is -CH
3
, R
3
 is -CH
2
-O-CH
3
, and Z represents -CO-CH
3
, 
-CO-O-C
2
H
5
, -CO-NH-phenyl, -CO-NH-C
2
H
5
, -CO-C
2
H
5
 or 
-CO-phenyl.  

 
Compounds according to Claim 1, characterized in that
 
R
1
 is a methyl or ethyl group. 
Compounds according to at least one of Claims 1 and 
2, characterized in that
 
R
2
 represents a hydrogen atom, an alkyl group 
containing 1-10 carbon atoms, an acyl residue 

containing 1-10 carbon atoms, or a residue -CONHR
4
 or 
-COOR
4
,
 
   where R
4
 is a hydrogen atom, an alkyl or aryl 
residue containing 1-10 carbon atoms. 
Compounds according to Claim 3, characterized in that
 
R
2
 represents an alkyl group containing 1-6 carbon 
atoms, an acyl residue containing 1-6 carbon atoms, 

or
 
a residue -CONHR
4
 or -COOR
4
,
 
   where R
4
 is a hydrogen atom or an alkyl or aryl 
residue containing 1-6 carbon atoms. 
Compounds according to at least one of Claims 1 to 4, 
characterized in that R
3
 is a hydrogen atom. 
Compounds according to at least one of Claims 1 to 4, 
characterized in that R
3
 is an alkyl, aryl, aralkyl, 
or alkylaryl group containing 1-10 carbon atoms. 
Compounds according to Claim 6, characterized in that
 
R
3
 represents an alkyl group containing 1-10 carbon 
atoms. 
Compounds according to Claim 6, characterized in that
 
R
3
 represents an alkyl group containing 1-6 carbon 
atoms.  

 
Compounds according to at least one of Claims 1 to 4, 
characterized in that
 
R
3
 is a a residue -(CH
2
)
n
-CH
2
X,
 
   where n = 0, 1, or 2, X represents a fluorine, 

chlorine, bromine, or iodine atom, a cyano, acido, 
or rhodano group, a residue OR
5
 or SR
5
,
 
      R
5
 being a hydrogen atom, an alkyl residue 
containing 1-10 carbon atoms, or an acyl 

residue containing 1-10 carbon atoms. 
Compounds according to Claim 9, characterized in that
 
R
3
 is a a residue -(CH
2
)
n
-CH
2
X,
 
   where n = 0, 1, or 2, X represents a fluorine, 

chlorine, bromine, or iodine atom, a cyano, acido, 
or rhodano group, a residue OR
5
 or SR
5
,
 
      R
5
 being an alkyl residue containing 1-6 carbon 

atoms, or an acyl residue containing 1-6 carbon 
atoms. 
Compounds according to at least one of Claims 1 to 4, 
characterized in that
 
R
3
 represents a residue OR
5
,
 
   R
5
 being a hydrogen atom, an alkyl residue 
containing 1-10 carbon atoms, or an acyl residue 

containing 1-10 carbon atoms. 
Compounds according to Claim 11, characterized in 
that
 
R
3
 represents a residue OR
5
,
 
   R
5
 being an alkyl residue containing 1-6 carbon 
atoms, or an acyl residue containing 1-6 carbon 

atoms.  
 
Compounds according to at least one of Claims 1 to 4, 
characterized in that
 
R
3
 represents a residue -(CH
2
)
o
-CH=CH(CH
2
)
p
-R
6
,
 
   where o = 0, 1, 2, or 3 and p = 0, 1, or 2, and R
6
 
represents a hydrogen atom, an alkyl group 

containing 1-10 carbon atoms, a hydroxyl group, an 
alkoxy or acyloxy group containing 1-10 carbon 

atoms. 
Compounds according to Claim 13, characterized in 
that
 
R
3
 represents a residue -(CH
2
)
o
-CH=CH(CH
2
)
p
-R
6
,
 
   where o = 0, 1, 2, or 3 and p = 0, 1, or 2, and R
6
 
represents an alkyl group containing 1-6 carbon 

atoms, an alkoxy or acyloxy group containing 1-6 
carbon atoms. 
Compounds according to at least one of Claims 1 to 4, 
characterized in that
 
R
3
 represents a a residue -(CH
2
)
q
C≡CR
7
,
 
   where q = 0, 1, or 2, and R
7
 represents a hydrogen 
atom, a fluorine, chlorine, bromine, or iodine 

atom, an alkyl residue containing 1-10 carbon 
atoms, or an acyl residue containing 1-10 carbon 

atoms. 
Compounds according to Claim 15, characterized in 
that
 
R
3
 represents a a residue -(CH
2
)
q
C≡CR
7
,
 
   where q = 0, 1, or 2, and R
7
 represents an alkyl 
residue containing 1-6 carbon atoms, or an acyl 

residue containing 1-6 carbon atoms. 
Compounds according to at least one of Claims 1 to 
16, characterized in that
  
 

Z represents a hydrogen atom, an alkyl residue 
containing
 
1-10 carbon atoms, an acyl residue containing 1-10 

carbon atoms, a
 
residue -CONHR
4
 or -COOR
4
,
 
   where R
4
 is a hydrogen atom or an alkyl residue 
containing 1-10 carbon atoms. 
Compounds according to Claim 17, characterized in 
that
 
Z represents an alkyl residue containing 1-6 carbon 

atoms, an acyl residue containing 1-6 carbon atoms, a 
residue -CONHR
4
 or -COOR
4
,
 
   where R
4
 is a hydrogen atom or an alkyl residue 
containing 1-6 carbon atoms. 
Compounds according to at least one of Claims 1 to 
16, characterized in that
 
Z represents an alkaline or alkaline-earth metal 

atom. 
Compounds according to Claim 1, namely 

11β-[4-(hydroximinomethyl)phenyl]-17β-hydroxy-17α-methoxymethyl-estra-4,9-diene-3-on, 
11β-[4-(hydroximinomethyl)phenyl]-17β-hydroxy-17α-ethoxymethyl-estra-4,9-diene-3-on, 
11β-[4-(hydroximinomethyl)phenyl]-17β-hydroxy-17α-n-propoxymethyl-estra-4,9-diene-3-on, 
11β-[4-(hydroximinomethyl)phenyl]-17β-hydroxy-17α-i-propoxymethyl-estra-4,9-diene-3-on, 
11β-[4-(hydroximinomethyl)phenyl]-17β-methoxy-17α-methoxymethyl-estra-4,9-diene-3-on,  

 
11β-[4-(hydroximinomethyl)phenyl]-17β-methoxy-17α-ethoxymethyl-estra-4,9-diene-3-on, 
11β-[4-(hydroximinomethyl)phenyl]-17β-hydroxy-17α-(3-hydroxyprop-1-in-yl)-estra-4,9-diene-3-on, 
11β-[4-(hydroximinomethyl)phenyl]-17β-methoxy-17α-(3-hydroxyprop-1-in-yl)-estra-4,9-diene-3-on, 
11β-[4-(hydroximinomethyl)phenyl]-17β-hydroxy-17α-Z-(3-hydroxypropenyl)-estra-4,9-diene-3-on, 
11β-[4-(hydroximinomethyl)phenyl]-17β-methoxy-17α-Z-(3-hydroxypropenyl)-estra-4,9-diene-3-on, 
17α-chloromethane-11β-[4-(hydroximinomethyl)phenyl]-17β-hydroxy-estra-4,9-diene-3-on, 
17α-chloromethane-11β-[4-(hydroximinomethyl)phenyl]-17β-methoxy-estra-4,9-diene-3-on, 
17α-cyanomethyl-11β-[4-(hydroximinomethyl)phenyl]-17β-hydroxy-estra-4,9-diene-3-on, 
17α-cyanomethyl-11β-[4-(hydroximinomethyl)phenyl]-17β-methoxy-estra-4,9-diene-3-on, 
17α-acidomethyl-11β-[4-(hydroximinomethyl)phenyl]-17β-methoxy-estra-4,9-diene-3-on, 
11β-[4-(hydroximinomethyl)phenyl]-17β-methoxy-17α-methylthiomethyl-estra-4,9-diene-3-on, 
11β-[4-(methyloximinomethyl)phenyl]-17β-methoxy-17α-methoxymethyl-estra-4,9-diene-3-on, 
11β-[4-(methyloximinomethyl)phenyl]-17β-hydroxy-17α-methoxymethyl-estra-4,9-diene-3-on, 

and  
 
11β-[4-(hydroximinomethyl)phenyl]-17β-ethoxy-17α-ethoxymethyl-estra-4,9-diene-3-on. 
Method for producing the compounds according to Claim 
1 and their pharmaceutically acceptable salts,
 
   characterized in that a compound of general formula 

II 

 
   wherein
 
   R
1
, R
2
 and R
3
 have the meaning as specified in 
claim 1,
 
is reacted with a compound of the general formula IIa 


NH2-O-Y
 
   where Y is a hydrogen atom, an alkyl residue 

containing 1-10 carbon atoms, an acyl residue 
containing 1-10 carbon atoms, or a 

residue -CONHR
4
 or -COOR
4
,
 
      where R
4
 has the meaning as specified in 
claim 1,
  
 

      and where the compound of the general formula IIa 
is present, if required, in the form of such 

compound, or from which the compound of the 
general formula IIa is released under the 

selected conditions of the reaction,
 
   the hydroximino group, if present, is esterified or 

etherified to produce compounds of the formula I, in 
which Z is not -H, and the resulting compound is 

optionally salified into its pharmaceutically 
acceptable salt. 
Method according to Claim 21, characterized in that 
the compounds of general formula II are reacted with 

the compounds of general formula IIa in equimolar 
quantities. 
Pharmaceutical compositions, characterized in that 
they contain at least one compound according to one 

of Claims 1 to 20. 
</CLAIMS>
</TEXT>
</DOC>
